Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Girentuximab I-124 - Heidelberg Pharma

Drug Profile

Girentuximab I-124 - Heidelberg Pharma

Alternative Names: 124-Iodine labeled monoclonal antibody G250; 124-Iodine labeled WX-G250; 124-Iodine-cG250; 124I-cG250; Redectane

Latest Information Update: 04 Jan 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Wilex
  • Developer Heidelberg Pharma AG
  • Class Antibody diagnostics; Monoclonal antibodies
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Renal cell carcinoma

Most Recent Events

  • 20 Dec 2017 Wilex withdraws the phase III REDECT 2 trial prior to enrolment due to new sponsor for Renal cell carcinoma diagnosis in USA (IV) (NCT01762592)
  • 16 Jan 2017 Girentuximab I-124 licensed to Telix Pharmaceuticals worldwide
  • 25 Apr 2016 Girentuximab I-124 is available for licensing as of 25 Apr 2016. http://www.wilex.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top